SMARCB1 and ovarian cancer: Ten SNVs were found to be associated with cancer risk in other studies: SNVs in PGR were associated with ovarian cancer risk, in BRCA2 was associated with breast cancer risk (even it was not a founder mutation), in CYP1A1 and ERBB2 were implicated in lung cancer risk, in MSH6, MLH1 and DCC could increase risk of colorectal cancer, SNV in PTCH1 was associated with increased risk of skin cancer, and synonymous change of SMARCB1 was associated with hematopoietic, lymphoid and CNS malignancies.